News | January 03, 2024
The acquisition is done through cash consideration, by way of conversion of SAFE (Simple Agreement for Future Equity) investment of US$ 2 Million to Preferred A-1 Shares
This acquisition marks Max Healthcare's entry into Lucknow
his marks the 12th formulation facility under Akums, and the second in Baddi, a strategic move with an aim to enhance Akums’ manufacturing capabilities.
The acquisition will enable Cupid Limited to amplify its production capacity by 1.5 times the existing output
Covaris is a global leader in the development and deployment of end-to-end solutions for high-throughput genomic and proteomic analysis
Laurus Labs concluded the acquisition by securing the remaining 8,333 equity shares from the promoter group shareholders
Zydus will pay an upfront consideration of GBP 68 million and yearly earn-outs until 2026
Clinical Trial Data Services supports small to midsize sponsor companies helping them to take the next step towards market approval for their drug or device product.
VaxTRIALS Adds a New Latin America Base and Greater Vaccine Research Depth
Subscribe To Our Newsletter & Stay Updated
